Industries > Pharma > Global Human Microbiome Therapeutics Market Forecast 2019-2029

Back to Pharma Reports

Global Human Microbiome Therapeutics Market Forecast 2019-2029

Gastrointestinal Disorders, Infectious Diseases, Metabolic Disorders, Dermatological Conditions, Other Disorders

PUBLISHED: 24 April 2019

PAGES: 250

PRODUCT CODE: PHA0416

SUBMARKET: Regional Markets

SKU: PHA0416 Categories: Pharma, Regional Markets Tags: PHA0377, PHA0416, PHA0441

The global human microbiome therapeutics market is estimated to grow at a CAGR of 60.2% in the first half of the forecast period. The global human microbiome therapeutics market is estimated to reach $1bn in 2024.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 250-page report you will receive 106 tables and 47 figures– all unavailable elsewhere.

The 250-page report provides clear detailed insight into the global human microbiome therapeutics market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

• Global Human Microbiome Therapeutics Market forecast from 2019-2029

• Global Human Microbiome Therapeutics Market revenue forecast 2019-2029 by Sector:
• Gastrointestinal Disorders
• Infectious Diseases
• Metabolic Diseases
• Dermatological Conditions
• Other Disorders

• Global Human Microbiome Therapeutics Market revenue forecast 2019-2029 by Region:
• U.S.
• EU5: Germany, France, U.K., Italy, Spain
• Japan
• Rest of the World

The human microbiome market revenue forecast 2019-2029 for the US, EU5 and Japan markets are further broken down by sector.

• This report discusses the top 20 companies in the human microbiome therapeutics market:
• 4D Pharma
• AOBiome Therapeutics
• C3J Therapeutics
• Caelus Health
• Enterome Bioscience
• Ferring Pharmaceuticals
• Finch Therapeutics/Crestovo
• IGEN BIOTECH GROUP
• Immuron
• Intrexon Corporation
• MaaT Pharma
• MatriSys Biosystem
• Microbiome Therapeutics LLC
• Osel
• Ritter Pharmaceuticals
• Second Genome
• Seres Therapeutics
• Synlogic
• Synthetic Biologics
• Vedanta Biosciences

This report discusses collaborations and acquisition, recent developments, drugs developments and key pipeline products

• This report lists and discusses the main pipeline products in these main sectors: gastrointestinal disorders submarket, metabolic disorders submarket, infectious diseases submarket, dermatological disorders submarket and other disorders submarket.

• Qualitative analysis of the human microbiome therapeutics market in the form of a SWOT Analysis.

• Key Questions Answered by this Report:
• How is the market for human microbiome therapeutics evolving?
• What is driving and restraining the human microbiome therapeutics market dynamics?
• What are the market shares of the submarkets for gastrointestinal disorders, infectious diseases, metabolic diseases, dermatological conditions, and other disorders from the overall human microbiome therapeutics market?
• How will each of the submarket segments within the human microbiome therapeutics market grow over the forecast period and how much revenue will these submarkets account for in 2029?
• How will the market shares for each of the submarkets within the human microbiome therapeutics market develop from 2019 to 2029?
• Which submarkets will be the main driver of growth in the overall market from 2019 to 2029?
• How will the regional market shares in the human microbiome therapeutics market change by 2029 and which geographical region will lead the market in 2029?

Visiongain’s study is intended for anyone requiring commercial analyses for the global human microbiome therapeutics market. You find data, trends and predictions.

Buy our report today Human Microbiome Therapeutics Market Analysis: Gastrointestinal Disorders, Infectious Diseases, Metabolic Disorders, Dermatological Conditions, Other Disorders.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

1. Report Overview

1.1 Global Human Microbiome Therapeutics: Market Overview

1.2 Global Human Microbiome Therapeutics: Market Segmentation

1.3 Why You Should Read This Report

1.4 How This Report Delivers

1.5 Key Questions Answered by This Analytical Report

1.6 Who Is This Report For?

1.7 Methodology

1.8 Frequently Asked Questions (FAQ)

1.9 Associated Reports

1.10 About Visiongain

2. An Introduction to Human Microbiome

2.1 The Pharmaceutical Industry: A Brief Introduction

2.2 Human Microbiota in Health

2.2.1 Microbiome-Host Interaction

2.2.2 Human Microbiota Ecosystems

2.3 Human Microbiota in Disease

2.3.1 Role of Microbiota in Health and Disease (Human Microbiota in Health)

2.4 Microbiome Projects under development

2.5 Hindrances for Microbiome as therapy

2.6 Unmet needs of Microbiome

3. The Global Burden of Human Microbiome Diseases

4. Human Microbiome Therapeutics: Market Segmentation

4.1 Gastrointestinal Disorders

4.1.1 Classification of Gastrointestinal Disorders

4.1.2 Role of Microbiota in Gastrointestinal Disorders

4.2 Infectious Disorders

4.2.1 Classification of Infectious Disease

4.2.2 Role of Microbiota in Infectious Disease

4.3 Metabolic & Liver Disorders

4.3.1 Classification of Metabolic & Liver Disorder

4.3.2 Role of Microbiota in Metabolic Disorders

4.4 Dermatological Conditions

4.4.1 Classification of Dermatological Conditions

4.4.2 Role of Microbiota in Dermatological Conditions

5. Phases of Clinical Trials

6. Human Microbiome Therapeutics: Market Definition

6.1 The Global Human Microbiome Therapeutics Market, 2019-2029

6.2 The Global Human Microbiome Therapeutics Market: Market Overview

6.3 The Global Human Microbiome Therapeutics In 2020

6.4 The Global Human Microbiome Therapeutics Market Forecast 2019-2029

6.5 Human Microbiome Therapies: Changing Market Shares by Sector 2019-2029

7. Global Human Microbiome Therapeutics Market by Sector: Market Forecast 2019-2029

7.1 Gastrointestinal Disorders Submarket Forecast 2019-2029

7.2 Infectious Diseases Submarket Forecast 2019-2029

7.3 Metabolic Diseases Submarket Forecast 2019-2029

7.4 Dermatological Conditions Submarket Forecast 2019-2029

7.5 Other Disorders (Cardiovascular, CNS, Cancer) Submarket Forecast 2019-2029

8. Global Microbiome Therapeutics Market Potential

8.1 Microbiome Therapeutics Market Potential for GI Disorders

8.2 Microbiome Therapeutics Market Potential for Infectious Disorders

8.3 Microbiome Therapeutics Market Potential for Metabolic Disorders

8.4 Microbiome Therapeutics Market Potential for Dermatological Conditions

8.5 Microbiome Therapeutics Market Potential for Other Disorders

9. Leading National Markets for Human Microbiome Therapies: Market Forecast 2019-2029

9.1 The Human Microbiome Therapeutics Market by Region

9.1.1 Global Distribution of Human Microbiome Therapeutics, 2021

9.2 Leading National Markets: Forecast 2019-2029

9.2.1 Changing Market Shares by Region, 2019-2029

9.3 United States

9.3.1 The United States Human Microbiome Therapeutics Market: Market Forecast 2019-2029

9.3.2 The United States Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%) by Sector, 2019-2029

9.3.2.1 The United States Human Microbiome Therapies: Changing Market Shares by Sector 2019-2029

9.4 EU5

9.4.1 EU5 Human Microbiome Therapeutics Market: Market Forecast 2019-2029

9.4.1.1 EU5 Markets: Changing Market Shares by Country, 2019-2029

9.4.2 EU5 Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%) by Sector, 2019-2029

9.4.2.1 EU5 Human Microbiome Therapies: Changing Market Shares by Sector 2019-2029

9.5 Germany

9.5.1 German Human Microbiome Therapeutics Market: Market Forecast 2019-2029

9.6 France

9.6.1 French Human Microbiome Therapeutics Market: Market Forecast 2019-2029

9.7 UK

9.7.1 UK Human Microbiome Therapeutics Market: Market Forecast 2019-2029

9.8 Italy

9.8.1 Italian Human Microbiome Therapeutics Market: Market Forecast 2019-2029

9.9 Spain

9.9.1 Spanish Human Microbiome Therapeutics Market: Market Forecast 2019-2029

9.10 Japan

9.10.1 The Cost of Treatment in Japan

9.10.2 Japanese Pharmaceutical Industry Regulatory Reform

9.10.3 Japanese Human Microbiome Therapeutics Market Forecast 2019-2029

9.10.4 Japan Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%) by Sector, 2019-2029

9.10.4.1 Japan Human Microbiome Therapies: Changing Market Shares by Sector, 2019-2029

9.11 Rest of the World

9.11.1 Rest of the World Human Microbiome Therapeutics Market: Market Forecast 2019-2029

10. Leading Companies in the Human Microbiome Therapeutics Market, 2019-2029

10.1 4D Pharma Plc.

10.1.1 4D Pharma: Collaborations and Acquisitions

10.1.2 4D Pharma: Microbiome Drugs Development Pipeline, 2018

10.1.3 4D Pharma: Recent Developments

10.1.4 4D Pharma: Key Pipeline Products

10.2 Synthetic Biologics

10.2.1 Synthetic Biologics: Collaborations and Agreement

10.2.2 Synthetic Biologics: Drug Development Pipeline, 2018

10.2.3 Synthetic Biologics: Recent Developments

10.2.4 Synthetic Biologics Key Pipeline Products,2018

10.3 Seres Therapeutics

10.3.1 Seres Therapeutics: Collaborations and Agreement

10.3.2 Seres Therapeutics: Drug Development Pipeline, 2018

10.3.3 Seres Therapeutics: Key Pipeline Products

10.4 Ferring Pharmaceuticals

10.4.1 Ferring Pharmaceuticals: Collaborations and Agreement

10.4.2 Ferring Pharmaceuticals: Drug Development Pipeline, 2018

10.4.3 Ferring Pharmaceuticals: Key Pipeline Products, 2018

10.5 AOBiome Therapeutics

10.5.1 AOBiome Therapeutics: Collaborations and Agreement

10.5.2 AOBiome Therapeutics: Drug Development Pipeline, 2018

10.5.3. AOBiome Therapeutics: Key Pipeline Products, 2018

10.6 Osel Inc.,

10.6.1 Osel Inc: Product Development Activities

10.6.2 Osel Inc: Drug Development Pipeline, 2018

10.6.3 Osel Inc: Key Pipeline Products, 2018

10.7 Immuron Ltd

10.7.1 Immuron: Collaboration and Agreement

10.7.2 Immuron: Drug Development Pipeline, 2018

10.7.3 Immuron: Key Pipeline Products, 2018

10.8 Ritter Pharmaceuticals, Inc.

10.8.1 Ritter Pharmaceuticals: Collaboration and Agreement

10.8.2 Ritter Pharmaceuticals: Drug Development Pipeline, 2018

10.8.3 Ritter Pharmaceuticals: Key Pipeline Products, 2018

10.9 Intrexon Corporation

10.9.1 Intrexon: Collaboration and Agreement

10.9.2 Intrexon: Drug Development Pipeline, 2018

10.9.3 Intrexon: Key Pipeline Products, 2018

10.10 Synlogic

10.10.1 Synlogic: Collaborations and Agreement

10.10.2 Synlogic: Drug Development Pipeline, 2018

10.10.3 Synlogic: Key Pipeline Products, 2018

10.11 C3J Therapeutics

10.11.1 C3J Therapeutics: Product Development Activities

10.11.2 C3J Therapeutics: Drug Development Pipeline, 2018

10.11.3 C3J Therapeutics: Key Pipeline Products, 2018

10.12 Finch Therapeutics/Crestovo

10.12.1 Finch/Crestovo: Collaboration and Agreement

10.12.2 Finch/Crestovo: Drug Development Pipeline, 2018

10.12.3 Finch/Crestovo: Key Pipeline Products, 2018

10.13 MaaT Pharma

10.13.1 MaaT Pharma: Collaboration and Agreement

10.13.2 MaaT Pharma: Drug Development Pipeline, 2018

10.14 IGEN BIOTECH GROUP

10.14.1 IGEN BIOTECH: Product Development Activities

10.14.2 IGEN BIOTECH: Key Pipeline Products

10.15 MatriSys Biosystem

10.15.1 MatriSys Biosystem: Product Development Activities

10.15.2 MatriSys Biosystem: Drug Development Pipeline, 2018

10.15.3 MatriSys Biosystem: Key Pipeline Products, 2018

10.16 Second Genome

10.16.1 Second Genome: Collaboration and Agreement

10.16.2 Second Genome: Drug Development Pipeline, 2018

10.16.3 Second Genome: Key Pipeline Products, 2018

10.17 Microbiome Therapeutics LLC

10.17.1 Microbiome Therapeutics: Product Development Activities

10.17.2 Microbiome Therapeutics: Drug Development Pipeline, 2018

10.17.3 Microbiome Therapeutics: Key Pipeline Products, 2018

10.18 Caelus Health

10.18.1 Caelus Health: Collaboration and Agreement

10.18.2 Caelus Health: Drug Development Pipeline, 2018

10.18.3 Caelus Health: Key Pipeline Products, 2018

10.19 Enterome Bioscience

10.19.1 Enterome Bioscience: Drug Development Pipeline, 2018

10.19.2 Enterome Bioscience: Collaboration and Agreement

10.19.3 Enterome Bioscience: Key Pipeline Products, 2018

10.20 Vedanta Biosciences

10.20.1 Vedanta Biosciences: Collaboration and Agreement

10.20.2 Vedanta Biosciences: Drug Development Pipeline, 2018

10.20.3 Vedanta Biosciences: Key Pipeline Products, 2018

11. Gastrointestinal Disorders: Key Products, 2018

11.1 RBX2600 & RBX7455: Ferring Pharmaceuticals

11.2 SER-109, SER287 & SER-262: Seres Therapeutics

11.3 Ribaxamase & SYN-010: Synthetic Biologics

11.4 IMM-529: Immuron

11.5 SGM-1019: Second Genome

11.6 Blautix, Thetanix & Rosburix: 4D Pharma

11.7 EB8018: Enterome Bioscience

12. Metabolic Disorders: Key Products, 2018

12.1 RP-G28: Ritter Pharmaceuticals

12.2 IMM-124E: Immuron

12.3 CP-001: Caelus Health

12.4 NM504 & NM505: Microbiome Therapeutics

12.5 SYNB1020: Synlogic

13. Infectious Diseases: Key Products, 2018

13.1 LACTIN-V: Osel

13.2 AOB-201: AOBiome Therapeutics

13.3 MaaT001: MaaT Pharma

13.4 CBM588: Osel Inc.

14. Dermatological Disorders: Key Products, 2018

14.1 AOB101, AOB102 & AOB103: AOBiome Therapeutics

14.2 MSB-01 & MSB-03: MatriSys Biosystem

15. Other Disorders: Key Products, 2018

15.1 AG013: Intrexon

15.2 AOB202 & AOB 203: AOBiome Therapeutics

15.3 C16G2: C3J Therapeutics

15.4 Microbiome Modulators: IGEN BIOTECH

16. Qualitative Analysis of the Human Microbiome Therapeutics, 2019-2029

16.1 Market Factors Influencing Human Microbiome Therapeutics Market

16.2 SWOT Analysis of the Global Human Microbiome Therapeutics Market, 2019-2029

16.2.1 Strengths

16.2.1.1 Novel & Efficient Therapies

16.2.1.2 A Healthy R&D Pipeline

16.2.1.3 Collaboration Among Key Industry Players

16.2.2 Weaknesses

16.2.2.1 Market Competition

16.2.2.2 Consumer Perception

16.2.2.3 Ethical Issues

16.2.2.4 R&D Capabilities

16.2.2.5 Knowledge Gaps

16.2.3 Opportunities

16.2.3.1 Growing Patient Pool

16.2.3.2 Unmet Clinical Needs in Several Disease Areas

16.2.3.3 Label Expansion

16.2.3.4 Economic Growth in Emerging Market Provide Opportunity for Expansion

16.2.4 Threats

16.2.4.1 Capital Intensive Research

16.2.4.2 Regulatory Approval

16.2.4.3 Price

16.2.4.4 Intellectual Property

17. Conclusions

17.1 Overview of Current Market Conditions and Market Forecast, 2019-2029

17.2 Leading Sectors in Human Microbiome Therapeutics in 2020

17.3 Leading Regions in the Human Microbiome Therapeutics Market in 2020

17.4 What Does the Future Hold for Microbiome Therapeutics?

Appendices

Associated Reports

Visiongain Report Sales Order Form

About Visiongain

Visiongain Report Evaluation Form

List of Tables

Table 4.1 Skin Disease and Related Microbiota

Table 5.1 Clinical Trial Phases

Table 6.1 Global Human Microbiome Therapeutics Market: Revenue ($m) and Market Share (%) by Sector, 2020

Table 6.2 Global Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%) by Sector, 2019-2029

Table 6.3 Global Human Microbiome Therapeutics Market Forecast: CAGR (%) by Sector

Table 6.4 Global Human Microbiome Therapeutics Market: Revenue ($m) and Market Share (%) by Sector, 2020, 2024, 2029

Table 7.1 Global Human Microbiome Therapeutics Market for Gastrointestinal Disorders: Market Forecast ($m, AGR% and CAGR%), 2019-2029

Table 7.2 Global Human Microbiome Therapeutics Market for Infectious Diseases: Market Forecast ($m, AGR% and CAGR%), 2019-2029

Table 7.3 Global Human Microbiome Therapeutics Market for Metabolic Diseases: Market Forecast ($m, AGR% and CAGR%), 2019-2029

Table 7.4 Global Human Microbiome Therapeutics Market for Dermatological Conditions: Market Forecast ($m, AGR% and CAGR%), 2019-2029

Table 7.5 Global Human Microbiome Therapeutics Market for Other Disorders: Market Forecast ($m, AGR% and CAGR%), 2019-2029

Table 9.1 Global Human Microbiome Therapeutics Market: Market Size ($m) and Market Share (%) by Region, 2021

Table 9.2 Global Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%) by Region, 2019-2029

Table 9.3 Global Human Microbiome Therapeutics Market Forecast: CAGR (%) by Region

Table 9.4 Global Human Microbiome Therapeutics Market Forecast: Market Share (%) by Region, 2021, 2024, and 2029

Table 9.5 The US Human Microbiome Therapeutics Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2019-2029

Table 9.6 US Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%), 2019-2029

Table 9.7 The United States Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%) by Sector, 2019-2029

Table 9.8 The United States Human Microbiome Therapeutics Market: Revenue ($m) and Market Share (%) by Sector, 2021, 2024, 2029

Table 9.9 EU5 Human Microbiome Drugs Market Forecast: Revenue ($m), Market Share (%) and CAGR (%), 2019-2029

Table 9.10 EU5 Human Microbiome Drugs Market: Revenue ($m), and Market Share (%) by Country, 2021

Table 9.11 EU5 Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%), by Country, 2019-2029

Table 9.12 EU5 Human Microbiome Therapeutics Market: Market Share (%) by Country, 2021, 2024, 2029

Table 9.13 EU5 Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%) by Sector, 2019-2029

Table 9.14 EU5 Human Microbiome Therapeutics Market: Revenue ($m) and Market Share (%) by Sector, 2021, 2024, 2029

Table 9.15 German Human Microbiome Therapeutics Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2021-2029

Table 9.16 German Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%), 2019-2029

Table 9.17 The French Human Microbiome Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2019-2029

Table 9.18 French Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%), 2019-2029

Table 9.19 The UK Human Microbiome Therapeutics Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2019-2029

Table 9.20 UK Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%), 2019-2029

Table 9.21 Italian Human Microbiome Therapeutics Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2019-2029

Table 9.22 Italian Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%), 2019-2029

Table 9.23 Spanish Human Microbiome Therapeutics Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2019-2029

Table 9.24 Spanish Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%), 2019-2029

Table 9.25 Japanese Human Microbiome Therapeutics Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2019-2029

Table 9.26 Japanese Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%), 2019-2029

Table 9.27 Japan Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%) by Sector, 2019-2029

Table 9.28 Japan Human Microbiome Therapeutics Market: Revenue ($m) and Market Share (%) by Sector, 2021, 2024, 2029

Table 9.29 The Rest of the World Human Microbiome Therapeutics Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2019-2029

Table 9.30 Rest of the World Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%), 2019-2029

Table 10.1 Pipeline Therapeutics by Companies

Table 10.2 4D Pharma: Company Overview, 2018

Table 10.3 4D Pharma: Key Pipeline Products, 2018

Table 10.4 Synthetic Biologics: Company Overview, 2018

Table 10.5 Synthetic Biologics: Key Pipeline Products, 2018

Table 10.6 Seres Therapeutics: Company Overview, 2018

Table 10.7 Clinical Trials Description

Table 10.8: Clinical Trials Description

Table 10.9 Clinical Trials Description

Table 10.10 Seres Therapeutics: Key Pipeline Products, 2018

Table 10.11 Ferring Pharmaceuticals: Company Overview, 2018

Table 10.12 Clinical Trials Description

Table 10.13 Clinical Trials Description

Table 10.14 Ferring Pharmaceuticals: Key Pipeline Products, 2018

Table 10.15 AOBiome, LLC: Company Overview, 2018

Table 10.16 Clinical Trials Description

Table 10.17 AOBiome Therapeutics: Key Pipeline Products, 2018

Table 10.18 Osel Inc: Company Overview, 2018

Table 10.19 Clinical Trials Description

Table 10.20 Osel Inc: Key Pipeline Products, 2018

Table 10.21 Immuron Ltd: Company Overview, 2018

Table 10.22 Clinical Trials Description

Table 10.23 Clinical Trials Description

Table 10.24 Key Pipeline Products, 2018

Table 10.25 Ritter Pharmaceuticals, Inc.: Company Overview, 2018

Table 10.26 Clinical Trials Description

Table 10.27 Ritter Pharmaceuticals: Key Pipeline Products, 2018

Table 10.28 Intrexon Corporation: Company Overview, 2018

Table 10.29 Clinical Trials Description

Table 10.30 Intrexon: Key Pipeline Products, 2018

Table 10.31 Synlogic: Company Overview, 2018

Table 10.32 Synlogic: Key Pipeline Products, 2018

Table 10.33 C3J Therapeutics: Company Overview, 2018

Table 10.34 Clinical Trials Description

Table 10.35 C3J Therapeutics: Key Pipeline Products, 2018

Table 10.36 Finch Therapeutics: Company Overview, 2018

Table 10.37 Clinical Trials Description

Table 10.38 Finch/Crestovo: Key Pipeline Products, 2018

Table 10.39 MaaT Pharma: Company Overview, 2018

Table 10.40 Clinical Trials Description

Table 10.41 IGEN BIOTECH GROUP: Company Overview, 2018

Table 10.42 IGEN BIOTECH: Key Pipeline Products

Table 10.43 MatriSys Biosystem: Company Overview, 2018

Table 10.44 MatriSys Biosystem: Key Pipeline Products, 2018

Table 10.45 Second Genome: Company Overview, 2018

Table 10.46 Second Genome: Key Pipeline Products, 2018

Table 10.47 Microbiome Therapeutics: Company Overview, 2018

Table 10.48 Clinical Trials Description

Table 10.49 Microbiome Therapeutics: Key Pipeline Products, 2018

Table 10.50 Caelus Health: Company Overview, 2018

Table 10.51 Key Pipeline Products, 2018

Table 10.52 Enterome Bioscience: Company Overview, 2018

Table 10.53 Clinical Trials Description

Table 10.54 Enterome Bioscience: Key Pipeline Products, 2018

Table 10.55 Vedanta Biosciences: Company Overview, 2018

Table 10.56 Vedanta Biosciences: Key Pipeline Products, 2018

Table 11.1 Gastrointestinal Disorders Drugs Pipeline: Key Drugs, 2018

Table 12.1 Metabolic Disorders Drugs Pipeline, 2018

Table 13.1 Infectious Disease Drugs Pipeline: Key Products, 2018

Table 14.1 Dermatological Disorders Drugs Pipeline: Key Products, 2018

Table 15.1 Other Disorders Drugs Pipeline: Key Products, 2018

Table 16.1 SWOT Analysis of the Global Human Microbiome Therapeutics Market, 2019-2029

Table 16.2 World 65+ Population Forecast: Size (m), AGR (%), CAGR (%), 2017-2028

Table 17.1 Global Human Microbiome Therapeutics: Market Forecast ($m, CAGR%), 2020, 2024 and 2029

Table 17.2 The Global Human Microbiome Therapeutics Market: Market Forecast ($m) by Region, 2020, 2024, 2029

List of Figures

Figure 1.1 Global Human Microbiome Therapeutics Market: Market Sectors

Figure 2.1 Role of Human Microbiota in Various Diseases

Figure 6.1 Global Human Microbiome Therapeutics Market: Revenue ($m) by Sector, 2020

Figure 6.2 Global Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%), 2019-2029

Figure 6.3 Global Human Microbiome Therapeutics Market Forecast: CAGR (%) by Sector, 2024-2029

Figure 6.4 Global Human Microbiome Therapeutics Market: Market Share (%) by Sector, 2020

Figure 6.5 Global Human Microbiome Therapeutics Market: Market Share (%) by Sector, 2024

Figure 6.6 Global Human Microbiome Therapeutics Market: Market Share (%) by Sector, 2029

Figure 7.1 Global Human Microbiome Therapeutics Market for Gastrointestinal Disorders: Market Forecast ($m), 2019-2029

Figure 7.2 Global Human Microbiome Therapeutics Market for Infectious Diseases: Market Forecast ($m), 2019-2029

Figure 7.3 Global Human Microbiome Therapeutics Market for Metabolic Diseases: Market Forecast ($m), 2019-2029

Figure 7.4 Global Human Microbiome Therapeutics Market for Dermatological Conditions: Market Forecast ($m), 2019-2029

Figure 7.5 Global Human Microbiome Therapeutics Market for Other Disorders: Market Forecast ($m), 2019-2029

Figure 9.1 Global Human Microbiome Therapeutics Market: Market Size ($m) by Region, 2021

Figure 9.2 US, EU, Japan and ROW Human Microbiome Therapeutics Market: Market Forecast ($m), 2019-2029

Figure 9.3 Global Human Microbiome Therapeutics Market Forecast: CAGR (%) by Region

Figure 9.4 Global Human Microbiome Therapeutics Market Forecast: CAGR (%) by Region, 2024-2029

Figure 9.5 Global Human Microbiome Therapeutics Market Forecast: CAGR (%) by Region, 2021-2029

Figure 9.6 Global Human Microbiome Therapeutics Market Forecast: Market Share (%) by Region, 2021

Figure 9.7 Global Human Microbiome Therapeutics Market Forecast: Market Share (%) by Region, 2024

Figure 9.8 Global Human Microbiome Therapeutics Market Forecast: Market Share (%) by Region, 2029

Figure 9.9 US Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%), 2019-2029

Figure 9.10 The United States Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%) by Sector, 2019-2029

Figure 9.11 The United States Human Microbiome Therapeutics Market: Market Share (%) by Sector, 2021

Figure 9.12 The United States Human Microbiome Therapeutics Market: Market Share (%) by Sector, 2024

Figure 9.13 The United States Human Microbiome Therapeutics Market: Market Share (%) by Sector, 2029

Figure 9.14 EU5 Human Microbiome Drugs Market: Revenue ($m) by Country, 2021

Figure 9.15 Germany, France, UK, Italy, and Spain Human Microbiome Drugs Market: Market Forecast ($m), 2019-2029

Figure 9.16 EU5 Human Microbiome Therapeutics Market: Market Share (%) by Country, 2021

Figure 9.17 The EU5 Human Microbiome Therapeutics Market: Market Share (%) by Country, 2024

Figure 9.18 The EU5 Human Microbiome Therapeutics Market: Market Share (%) by Country, 2029

Figure 9.19 EU5 Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%) by Sector, 2019-2029

Figure 19.20 EU5 Human Microbiome Therapeutics Market: Market Share (%) by Sector, 2021

Figure 19.21 EU5 Human Microbiome Therapeutics Market: Market Share (%) by Sector, 2024

Figure 19.22 EU5 Human Microbiome Therapeutics Market: Market Share (%) by Sector, 2029

Figure 9.23 German Human Microbiome Therapeutics Market: Market Forecast ($m), 2019-2029

Figure 9.24 French Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%), 2019-2029

Figure 9.25 UK Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%), 2019-2029

Figure 9.26 Italian Human Therapeutics Market: Market Forecast ($m, AGR%), 2019-2029

Figure 9.27 Spanish Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%), 2019-2029

Figure 9.28 Japanese Human Microbiome Therapeutics Market: Market Forecast ($m), 2019-2029

Figure 9.29 Japan Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%) by Sector, 2019-2029

Figure 9.30 Japan Human Microbiome Therapeutics Market: Market Share (%) by Sector, 2024

Figure 9.31 Japan Human Microbiome Therapeutics Market: Market Share (%) by Sector, 2029

Figure 9.32 Rest of the World Human Microbiome Therapeutics Market: Market Forecast ($m), 2019-2029

Figure 17.1 Global Human Microbiome Therapeutics: Market Forecast ($m), 2019- 2029

Figure 17.2 The Global Human Microbiome Therapeutics Market: Market Forecast ($m) by Region, 2019-2029

4D Pharma

4D Pharma Cork Limited

4D Pharma Leon

AbbVie S.à.r.l.

Accinov

ActoGeniX

Aju IB Investment

Ally Bridge Group

Amrita Therapeutics

AOBiome, LLC

AquaBounty Technologies

Arctic Aurora Life Science

Aspire Capital Fund

Assembly Biosciences

Azitra

BaseClear

BIOASTER

Biological & Popular Culture, Inc.

BiomX

Bio-Technology General

Blue Turtle Bio

Bristol-Myers Squibb

BYTC Corp

C3J Therapeutics

Caelus Health

Cd4 Biosciences, Inc.

Cedars-Sinai Medical Centre

Chengdu Sen Nuo Wei Biotechnology Co., Ltd

CLI Ventures

Codexis Laboratories Hungary Kft

CoreBiome

Crestovo

CRS Bio, Inc

DayTwo

Digitalis Ventures

Effective Pharmaceuticals, Inc.

Enterome Bioscience

Enterome SA

EnviroFlight, LLC

Epibiome

Epitope Pharmaceuticals, Inc.

Evelo Biosciences

Evolve BioSystems

Ferring Pharmaceuticals

Ferring Sas

Finch Therapeutics Group, Inc.

Finch Therapeutics

Genomatix Ltd.

Genten Therapeutics, Inc.

GenVec, Inc.

Global Bioscience Company

GT Biologics Limited

Hartlab LLC

Harvest Capital Strategies, LLC

HealthMine, Inc

IBBL

iCarbonX

Igen Biotech Group

ImmuneBiotech AB

Immuron, Ltd.

INC Research

INRA transfer

Intrexon

Intrexon Actobiotics N.V.

Intrexon Corporation

Intrexon Crop Protection

Intrexon Energy Partners II, LLC

Intrexon Energy Partners, LLC

Intrexon T1D Partners

Janssen Biotech

Johnson & Johnson

Kallyope

Kolu Pohaku Management, LLC

Kolu Pohaku Technologies

Leading Biosciences

LNC Therapeutics

Lundbeckfond Ventures

MaaT Pharma SA

MatriSys Bioscience

MatriSys Biosystem

Mayo Clinic

Medistem, Inc.

Medpace

Merck & Co., Inc.

Microbiome Therapeutics, LLC

Microbiomics Limited

Mirna Therapeutics

Nestle Health Science

Nitrocell

NIZO

Nubiyota

NuMe Health LLC

Okanagan Specialty Fruits Inc.

Omnes Capital

OpenBiome

OptiBiotix Health plc

OrbiMed HealthCare Fund Management

Osel, Inc.

OvaXon, LLC

Oxitec

Perceptive Advisors

Pfizer Venture Investments

Pharm-Olam International

Pipex Therapeutics, Inc

Precigen, Inc.

Prev AbR LLC

ProDigest

PureTech Health

Putney Drug Corp

Pylum Biosciences

Quorum Innovations

Rebiotix, Inc

Ritter Natural Sciences, LLC

Ritter Pharmaceuticals

Roche Venture Fund

Rock Springs Capital

S & I Ophthalmic

S-Biomedic

Second Genome

Seres Therapeutics

Seventure Partners

Shire

Solovax, Inc

SR One Venture Partners

Symberix

Symbiotic Health

Symbiotix Biotherapies

Synlogic, Inc.

Synthetic Biologics, Inc.

Synthetic Biomics Inc.

Synthetic Genomics, Inc.

Takeda

TargEDys

Tech Coast Angels (TCA)

The Microbiota Company Limited

Trans Ova Genetics LC

Tucana Health Limited

Vedanta Biosciences Inc.

Veristat

Vertex Pharmaceuticals Inc.

Whole Biome

Xycrobe Therapeutics

List of Organizations Mentioned in the Report

Alimentary Pharmabiotic Centre

American Academy of Dermatology

APC Microbiome Institute

Central Drugs Standard Control Organisation (CDSCO)

French National Institute for Agricultural Research

Hadasit Medical Research Services & Development Ltd

Hadassah Medical Center

Health Canada

Institut National de la Recherche Agronomique

Integrium

John Theurer Cancer Center of Hackensack Meridian Health

King’s College London

La Trobe University

Lawrence Berkeley National Laboratory

Leiden University Medical Center

Mayo clinic

Medicines Control Council (MCC)

Medical University of Graz

Memorial Sloan Kettering Cancer Center

Ministry of Health, Labour and Welfare (MHLW)

Medicines and Healthcare products Regulatory Agency (MHRA)

Microbiome Institute at University College Cork

Monash University

Murdoch Children Research Institute

National Institute of Allergy and Infectious Diseases

NYU Langone Health

Orange Country Research Center

Pan American Health Organization (PAHO)

Roswell Park Comprehensive Cancer Center

Ruprecht-Karls-University Heidelberg

Saudi Food and Drug Authority (SFDA)

St. Joseph’s Hamilton

Stanford Cancer Institute

Therapeutic Goods Administration (TGA)

The Endocrine Society

The Parker Institute for Cancer Immunotherapy

University of British Columbia

University of California

University of Melbourne

University of Minnesota

University of Nebraska

University of Pennsylvania

University of South Alabama (USA) Mitchell Cancer Institute

University of Texas at Austin

University of Texas MD Anderson Cancer Center

University of Tokyo

USA Mitchell Cancer Center

World Health Organization (WHO)

World Intellectual Property Organization WIPO

World Trade Organization (WTO)

Download sample pages

Complete the form below to download your free sample pages for Global Human Microbiome Therapeutics Market Forecast 2019-2029

Download sample pages

Complete the form below to download your free sample pages for Global Human Microbiome Therapeutics Market Forecast 2019-2029

Case studies

Need customized work?

Report overview

Methodology

Client testimonials

Pharmaceutical industry associations

American Association of Colleges of Pharmacy
American College of Clinical Pharmacy
American Pharmacists Association
American Society for Pharmacy Law
American Society of Consultant Pharmacists
American Society of Health-System Pharmacists
Association of Special Pharmaceutical Manufacturers
Australian College of Pharmacy
Biotechnology Industry Organization
Canadian Pharmacists Association
Canadian Society of Hospital Pharmacists
Chinese Pharmaceutical Association
College of Psychiatric and Neurologic Pharmacists
Danish Association of Pharmaconomists
European Association of Employed Community Pharmacists in Europe
European Medicines Agency
Federal Drugs Agency
General Medical Council
Head of Medicines Agency
International Federation of Pharmaceutical Manufacturers & Associations
International Pharmaceutical Federation
International Pharmaceutical Students’ Federation
Medicines and Healthcare Products Regulatory Agency
National Pharmacy Association
Norwegian Pharmacy Association
Ontario Pharmacists Association
Pakistan Pharmacists Association
Pharmaceutical Association of Mauritius
Pharmaceutical Group of the European Union
Pharmaceutical Society of Australia
Pharmaceutical Society of Ireland
Pharmaceutical Society Of New Zealand
Pharmaceutical Society of Northern Ireland
Professional Compounding Centers of America
Royal Pharmaceutical Society
The American Association of Pharmaceutical Scientists
The BioIndustry Association
The Controlled Release Society
The European Federation of Pharmaceutical Industries and Associations
The European Personalised Medicine Association
The Institute of Clinical Research
The International Society for Pharmaceutical Engineering
The Pharmaceutical Association of Israel
The Pharmaceutical Research and Manufacturers of America
The Pharmacy Guild of Australia
The Society of Hospital Pharmacists of Australia

Connect with us

Visiongain Pharma

Latest Pharma news

Visiongain Publishes Allergy Immunotherapy Market Report 2023-2033

The global Allergy Immunotherapy market is projected to grow at a CAGR of 7.6% by 2033

31 May 2023

READ

Visiongain Publishes AI-based Clinical Trial Solution Providers Market Report 2023-2033

The global AI-based Clinical Trial Solution Providers market was valued at US$1,232.0 million in 2022 and is projected to grow at a CAGR of 23.3% during the forecast period 2023-2033.

26 May 2023

READ

Visiongain Publishes Vaccine Contract Manufacturing Market Report 2023-2033

The global Vaccine Contract Manufacturing Market is projected to grow at a CAGR of 13.2% by 2033

24 May 2023

READ

Visiongain Publishes Cell & Gene Therapy Cold Chain Logistics Market Report 2023-2033

The global Cell & Gene Therapy Cold Chain Logistics market is projected to grow at a CAGR of 15% by 2033

23 May 2023

READ

Industries > Pharma > Global Human Microbiome Therapeutics Market Forecast 2019-2029

Back to Pharma Reports

Global Human Microbiome Therapeutics Market Forecast 2019-2029

Gastrointestinal Disorders, Infectious Diseases, Metabolic Disorders, Dermatological Conditions, Other Disorders

Download sample pages

Related reports

Generic Drugs Market Forecast 2019-2029

Global Anti-Obesity Drugs Market Forecast 2018-2028

Global Probiotics Market Forecast 2018-2028

Global Transplant Market Forecast 2019-2029

Dermatological Drugs Market Forecast 2018-2028

Advanced Wound Care Market Forecast 2018-2028

Global Precision Medicine Market Forecast 2019-2029

Biologics Market Trends and Forecasts 2018-2028

Global Antibacterial Drugs Market 2019-2029

Global Infectious Disease Diagnostics Market Forecast 2017-2027

Download sample pages

Share

Connect with us

Latest Pharma news

Visiongain Publishes Allergy Immunotherapy Market Report 2023-2033

Visiongain Publishes AI-based Clinical Trial Solution Providers Market Report 2023-2033

Visiongain Publishes Vaccine Contract Manufacturing Market Report 2023-2033

Visiongain Publishes Cell & Gene Therapy Cold Chain Logistics Market Report 2023-2033

Our Clients